肝靶向纳米给药系统治疗肝纤维化的研究进展

肝纤维化是慢性肝损伤早期重要的病理特征,可以通过药物治疗逐渐逆转消退.传统药物存在药效下降及对正常器官的毒副作用等问题.运用纳米技术开发的给药系统,可以保护药物,克服生物屏障,将药物定向递送到指定区域发挥作用.在肝损伤修复过程中,肝实质细胞(HC)、肝星状细胞(HSC)、枯否细胞(KC)和肝窦内皮细胞(LSEC)均起到关键作用.肝靶向纳米药物可专门针对肝脏细胞,基于它们的摄取能力和调节能力实现药物靶向性,更有效地发挥药物抗炎和抗纤维化治疗作用,降低毒副作用,逆转肝纤维化.就纳米技术应用于肝纤维化靶向治疗的研究进展作一综述.

Progress in targeted nanoparticle for the therapy of liver fibrosis

Liver fibrosis is an important pathological hallmark in the early stage of chronic liver injury,which can be gradually treated by drug treatment.Traditional medicine has limited therapeutic effect and is toxic to the normal organs.The drug delivery system based on nanotechnology can overcome the deficiency of traditional drugs to protect the drug which can be delivered to the target cells.Four major types of cells in liver play critical role in liver fibrogenesis,including hepatocytes,hepatic stellate cells,kupffer cells and hepatic sinusoidal endothelial cells.Liver targeted nanomedicine can be delivered to these liver cells based on their material and functional modification and enhance anti-inflammatory and anti-fibrotic effect.They also can reduce the toxic side effects and reverse liver fibrosis.This article gives an overview on current strategies of the application of nanotechnology in targeting treatment for liver fibrosis.